Do you have non-small-cell lung cancer? Did your cancer get worse after, or while you were on treatment? If so, you may be eligible to participate in a research study that uses your own modified immune cells as possible treatment.

This is a registry of childhood, adolescent, and young adult patients with cancer. This registry is for anyone diagnosed with cancer before the age of 40 years to establish a UNC-based resource for the prospective study of the long-term, treatment-related effects, particularly the early aging effects, of cancer and its treatment.

The purpose of this research study is to better understand, from the perspective of Black patients, whether telemedicine visits make prostate cancer decision making easier or harder. The COVID-19 pandemic made it more difficult for patients to see their doctors, but care could continue by having appointments via a computer or phone, which many prostate cancer doctors used. Whether in person or remote, successfully choosing a treatment for prostate cancer often uses shared decision making (SDM), the process where doctors and patients work together to make decisions that match what matters to patients, but it is unknown whether virtual appointments make discussions better or worse. Other studies have shown that Black patients may be less satisfied with their treatment choices than non-Black patients. Therefore, it is important that we understand how to improve the same quality of care for Black patients.

Have you been recently diagnosed with Diffuse Large B Cell Lymphoma? Are you over 75 years of age? If so, you may be able to take part in a research study looking at the safety of giving a new study drug CC-486 (oral azacitidine) in addition to the standard chemotherapy drug combination used to treat this disease.

To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.

To find the safest and most tolerable dose of CAR.B7-H3 T cells to administer in patients with relapsed/refractory platinum-resistant epithelial ovarian cancer.

Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.

Do you have mantle cell lymphoma or other non-Hodgkin lymphoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

The purpose of this study is to test whether giving the study drug acalabrutinib is safe and could help control B-cell Non-Hodgkin CNS lymphoma that have not gone away, or have come back, after the first round of treatment.